Schizoaffective Disorder, Schizophrenia
Conditions
Brief summary
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and schizoaffective disorder in a Latin American population.
Interventions
DRUGZiprasidone
IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of schizophrenia or schizoaffective disorder. * Inpatients with acute exacerbation of psychotic symptoms. * Patients with a minimum score of 40 on the BPRS scale (1-7).
Exclusion criteria
* Concurrent treatment with antipsychotic agents at study drug initiation (within 12 hours prior to study drug initiation); for depot agents a period of two weeks or one cycle, whichever is the longer, must occur between last administration and study drug initiation. * Treatment with antidepressants or mood stabilizers within 7 days of start of ziprasidone. * Patients currently receiving clozapine. * Patients at immediate risk of committing harm to self or others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to endpoint in Brief Psychiatric Rating Scale (BPRS) total score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline to endpoint in Clinical Global Impressions-Severity (CGI-S) scale score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Simpson-Angus Scale (SAS) | Days 1 and 2 (IM), Day 4 (Switch), and Weeks 2 and 6 (PO) |
| Barnes Akathisia Scale (BAS) | Days 1 and 2 (IM), Day 4 (Switch), and Weeks 2 and 6 (PO) |
| Laboratory tests | Screening and Week 6 |
| Electrocardiogram | Screening and Week 6 |
| Change from baseline to endpoint in Clinical Global Impressions-Improvement (CGI-I) scale score | Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Abnormal Involuntary Movement Scale (AIMS) | Day 1 (IM), Day 4 (Switch), and Week 6 (PO) |
| Change from baseline to endpoint in Positive and Negative Syndrome Scale (PANSS) total score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Change from baseline to endpoint in Covi Anxiety Scale score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Change from baseline to endpoint in Positive PANSS subscale score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Change from baseline to endpoint in Negative PANSS subscale score | Screening, Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
| Adverse events | Days 1-3 (IM), Day 4 (Switch), Days 5-7 and Weeks 2, 4, and 6 (PO) |
Countries
Mexico
Outcome results
None listed